Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_4
1
33%
Ph phase_1
1
33%
Ph phase_3
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Terminated1
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

terminated133%
completed133%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1

Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial

NCT04413214
terminatedphase_3

Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

NCT04672564
unknownphase_4

The Clinical Study of Carrimycin on Treatment Patients With COVID-19

NCT04286503

Clinical Trials (3)

Showing 3 of 3 trials
NCT04413214Phase 1

Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial

Completed
NCT04672564Phase 3

Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

Terminated
NCT04286503Phase 4

The Clinical Study of Carrimycin on Treatment Patients With COVID-19

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3